Curing HCV infection with direct-acting antiretrovirals is associated with regression of liver fibrosis for most patients.
The researchers found a significant difference in mean time to direct-acting antiviral agent treatment among participants with public insurance payers compared with private insurance payers.
The neuropsychiatric symptoms associated with HCV infection are likely caused by the body's response to the virus' effects on brain function.
A robust anamnestic response was mounted in most adolescents when challenged with a dose of monovalent HBV vaccine.
Direct-acting antivirals are safe and effective in African-American patients with chronic HCV.
There is an opportunity to improve HCV treatment rates for people who inject drugs by integrating DAA therapy into current models of community-based addiction.
In high-volume centers, patients with liver metastases from colorectal cancer may often be eligible for minimally invasive liver surgery via laparoscopy, thereby reducing potential morbidity risks associated with open surgery.
All 20 recipients experienced HCV cure, good quality of life, excellent renal function.
Circulating hepatic markers may predict the risk for diabetes in women.
Drop in median price of WHO-prequalified generic tenofovir from 208 to 32 from 2004 to 2016
Investigators added hepatitis C virus and HIV screening tests to standard trauma activation laboratory orders.
Coordinated treatment programs may improve treatment outcomes in patients with hepatitis C infection.
Adults aged 25 to 34 show greatest relative increase in mortality, driven by alcoholic cirrhosis.
Adherence and completion to multidose vaccine schedules for hepatitis A, B, and A-B are low, thereby rendering vaccination ineffective.
Project ECHO at Los Angeles Christian Health Center contributes to improved care of HCV in underserved populations.
Patients with chronic hepatitis B have a lower risk of hepatic events if they achieve normal on-treatment ALT in the first 12 months of NA treatment.
Of the 2500 cases of hepatitis A infection reported between January 2017 and April 2018, 68% were among persons who reported drug use (injection and non-injection), homelessness, or both.
Successful DAA therapy may lead to cognitive improvement in several domains in HCV-infected patients.
Costs were significantly higher than total annual costs per matched control with similar comorbidities.
Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women
The Respectful & Equitable Access to Comprehensive Healthcare program obtained 93% of prior authorization approvals for hepatitis C medications.
Patients with mild, moderate renal impairment showed improvement in renal biomarkers over one year
A proposed novel Medicaid purchasing strategy is anticipated to increase access to medications that can eradicate hepatitis C virus infection without increasing costs at the state and federal levels.
A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.
Future studies might focus on the use of electronic medical record warning systems or other prompts to improve diagnostic test use in at-risk individuals.
Metabolic syndrome also associated with higher alanine aminotransferase levels longitudinally
Screening prevalence 11.5 to 12.8%; similar rate for cohort born from 1966 to 1985
In this large, real-world cohort of patients with chronic hepatitis C virus infection, equivalent sustained virologic response rates were found with both 8-week and 12-week treatment.
End-of-treatment HBsAg levels may be a clinically useful biomarker to predict HBV relapse in patients with chronic hepatitis B regardless of HBeAg status.
Increased adiposity in childhood may negatively impact liver function in children as young as 8 years old.